Aurinia Pharmaceuticals(AUPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AUPH Aurinia Pharmaceuticals

Trading 04-27 10:21:53 EDT

16.47

+0.49

+3.07%

High16.52	Low15.84	Vol158.93K
Open15.84	D1 Closing15.98	Amplitude4.26%
Mkt Cap2.14B	Tradable Cap2.11B	Total Shares129.94M
T/O2.57M	T/O Rate0.12%	Tradable Shares128.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AUPH","market":"US","secType":"STK","nameCN":"Aurinia Pharmaceuticals","latestPrice":16.47,"timestamp":1777299707486,"preClose":15.98,"halted":0,"volume":158933,"delay":0,"changeRate":0.030663329161451716,"floatShares":128000000,"shares":129938324,"eps":2.07,"marketStatus":"Trading","change":0.49,"latestTime":"04-27 10:21:53 EDT","open":15.842,"high":16.52,"low":15.84,"amount":2574280.077178,"amplitude":0.042553,"askPrice":16.46,"askSize":54,"bidPrice":16.45,"bidSize":104,"shortable":3,"etf":0,"ttmEps":2.07,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1777320000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":951454800000,"exchange":"NASDAQ","adjPreClose":15.98,"preHourTrading":{"tag":"盘前","latestPrice":15.82,"preClose":15.98,"latestTime":"09:29 EDT","volume":9151,"amount":146443.05035600002,"timestamp":1777296541038,"change":-0.16,"changeRate":-0.010013,"amplitude":0.095814},"postHourTrading":{"tag":"盘后","latestPrice":15.7683,"preClose":15.98,"latestTime":"18:54 EDT","volume":130424,"amount":2084128.65,"timestamp":1777071268833,"change":-0.2117,"changeRate":-0.013248,"amplitude":0.013248},"volumeRatio":1.098264,"impliedVol":0.4549,"impliedVolPercentile":0.5458},"requestUrl":"/m/hq/s/AUPH/wiki","defaultTab":"wiki","newsList":[{"id":"2629068875","title":"Aurinia Pharmaceuticals announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629068875","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629068875?lang=en_us&edition=fundamental","pubTime":"2026-04-22 04:33","pubTimestamp":1776803637,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals will hold its 2026 annual general meeting via live webcast on June 3, 2026.Shareholders will vote to elect five director nominees to serve until 2027 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 21, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL5SkvM0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625624519","title":"A Look At Aurinia Pharmaceuticals (AUPH) Valuation After Its Recent Leadership Overhaul","url":"https://stock-news.laohu8.com/highlight/detail?id=2625624519","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625624519?lang=en_us&edition=fundamental","pubTime":"2026-04-06 09:22","pubTimestamp":1775438570,"startTime":"0","endTime":"0","summary":"Leadership overhaul and fresh management lineup at Aurinia\nAurinia Pharmaceuticals (AUPH) has undergone a broad leadership reset, with Kevin Tang becoming Chief Executive Officer, Michael Hearne stepping in as Chief Financial Officer, and Ryan Cole taking on the Chief Operating Officer role.\nThese appointments follow the departure of former CEO Peter Greenleaf and several senior officers. They also bring in multiple executives with ties to Tang Capital Management, a shift that many investors...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/a-look-at-aurinia-pharmaceuticals-auph-valuation-after-its-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/a-look-at-aurinia-pharmaceuticals-auph-valuation-after-its-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624664225","title":"Aurinia Pharma to buy Kezar Life Sciences for $6.955 a share plus CVR","url":"https://stock-news.laohu8.com/highlight/detail?id=2624664225","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624664225?lang=en_us&edition=fundamental","pubTime":"2026-04-04 04:58","pubTimestamp":1775249915,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals agreed to acquire Kezar Life Sciences for USD 6.955 per share in cash plus a non-transferable contingent value right.CVR provides potential payouts tied to development or disposition of Kezar lead asset zetomipzomib, selected collaboration and asset-sale proceeds, and net cash above USD 50 million at closing.Aurinia plans to launch a tender offer by April 13, 2026, for all outstanding Kezar shares.Closing is expected in Q2 2026, subject to a majority of shares tendered and Kezar meeting a net-cash condition above USD 50 million.Tang Capital Partners, holding about 9.0% of Kezar shares, signed a tender and support agreement backing transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceutical","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDL9hGLjS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KZR","AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624682998","title":"Aurinia Pharmaceuticals CFO Michael Hearne files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2624682998","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624682998?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:22","pubTimestamp":1775161364,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals filed a Form 3 initial beneficial ownership statement for Chief Financial Officer Michael Hearne, dated March 23, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDLbDRghx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624829196","title":"Aurinia Pharma COO Ryan Cole files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2624829196","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624829196?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:22","pubTimestamp":1775161348,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals COO Ryan Cole filed an initial Form 3 beneficial ownership statement dated March 23, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDLByGyL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623229943","title":"Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and Aurinia Pharmaceuticals (AUPH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2623229943","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623229943?lang=en_us&edition=fundamental","pubTime":"2026-03-31 06:10","pubTimestamp":1774908607,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Terns Pharmaceuticals (TERN) and Aurinia Pharmaceuticals (AUPH). ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-terns-pharmaceuticals-tern-and-aurinia-pharmaceuticals-auph-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-terns-pharmaceuticals-tern-and-aurinia-pharmaceuticals-auph-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU0128526141.USD","LU0109394709.USD","LU0029874061.USD","LU0889565916.HKD","HCSG","BK4007","XBI","BK4137","LABU","AUPH","XLV","BK4581","LU0320765992.SGD","BK4139","TERN","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623326235","title":"Kezar Life Sciences takeover valuation ‘makes sense,’ says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2623326235","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623326235?lang=en_us&edition=fundamental","pubTime":"2026-03-31 03:56","pubTimestamp":1774900569,"startTime":"0","endTime":"0","summary":"After Aurinia Pharmaceuticals (AUPH) announced an agreement to acquire Kezar Life Sciences (KZR) for $6.955 in cash per share plus one non-transfer...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kezar-life-sciences-takeover-valuation-makes-sense-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kezar-life-sciences-takeover-valuation-makes-sense-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KZR","BK4139","AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623317885","title":"Aurinia to buy Kezar Life Sciences for USD 6.96 per share plus CVR","url":"https://stock-news.laohu8.com/highlight/detail?id=2623317885","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623317885?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:03","pubTimestamp":1774872182,"startTime":"0","endTime":"0","summary":"Aurinia agreed to acquire Kezar Life Sciences for USD 6.96 per share in cash.Kezar shareholders will also receive a non-transferable CVR tied to potential proceeds from zetomipzomib development or disposition, select collaboration and asset-sale proceeds, and excess closing net cash above USD 50 million.Aurinia plans to launch tender offer by April 13, 2026, for all outstanding Kezar shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire  on March 30, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL3PZ9wx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KZR","AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623736312","title":"Aurinia Pharmaceuticals Inc - CVR Includes Payments From Zetomipzomib, Everest, Enodia, and Net Cash Over $50 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2623736312","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623736312?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:00","pubTimestamp":1774872006,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA61LWRC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KZR","AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623350680","title":"How Aurinia’s Tang-Led C-Suite Overhaul Will Impact Aurinia Pharmaceuticals (AUPH) Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2623350680","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623350680?lang=en_us&edition=fundamental","pubTime":"2026-03-30 03:06","pubTimestamp":1774811202,"startTime":"0","endTime":"0","summary":"In March 2026, Aurinia Pharmaceuticals underwent a sweeping leadership overhaul, with Board Chair Kevin Tang becoming CEO and principal executive officer, joined by new CFO Michael Hearne, COO Ryan Cole, and Chief Scientific Officer Thomas Wei as several prior C-suite leaders departed.\nThis reshuffle consolidates operational control around Tang Capital–linked executives, signaling a potential shift in how Aurinia balances capital allocation, operations, and pipeline priorities.\nNext, we’ll...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/how-aurinias-tang-led-c-suite-overhaul-will-impact-aurinia-p","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/how-aurinias-tang-led-c-suite-overhaul-will-impact-aurinia-p","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","ISBC","BK4139","AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621707942","title":"MKT Capital ‘applauds’ Aurinia’s management transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2621707942","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621707942?lang=en_us&edition=fundamental","pubTime":"2026-03-23 23:06","pubTimestamp":1774278410,"startTime":"0","endTime":"0","summary":"MKT Capital, a long-term shareholder of Aurinia Pharmaceuticals (AUPH), issued a statement in response to the company’s announcement that Kevin Tan...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mkt-capital-applauds-aurinias-management-transition-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mkt-capital-applauds-aurinias-management-transition-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621702848","title":"Why Aurinia Pharmaceuticals Stock Is Surging Monday Morning","url":"https://stock-news.laohu8.com/highlight/detail?id=2621702848","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621702848?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:26","pubTimestamp":1774275960,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals shares are trading higher Monday after announcing a leadership transition seen as a sign of continuity and strategy.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/23/Doctor-holding-digital-tablet-at-meeting.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/23/Doctor-holding-digital-tablet-at-meeting.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/03/51407731/why-aurinia-pharmaceuticals-stock-is-surging-monday-morning","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/03/51407731/why-aurinia-pharmaceuticals-stock-is-surging-monday-morning","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621170364","title":"BRIEF-Aurinia Announces Management Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2621170364","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621170364?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:08","pubTimestamp":1774267734,"startTime":"0","endTime":"0","summary":"BRIEF-Aurinia Announces Management TransitionAurinia Pharmaceuticals Inc AUPH.O:AURINIA ANNOUNCES MANAGEMENT TRANSITIONAURINIA PHARMACEUTICALS INC - APPOINTS KEVIN TANG AS CEO SUCCEEDING PETER GREENLE","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nTUA5XDTX9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621708058","title":"Aurinia names Kevin Tang CEO, appoints Ryan Cole COO","url":"https://stock-news.laohu8.com/highlight/detail?id=2621708058","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621708058?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:02","pubTimestamp":1774267344,"startTime":"0","endTime":"0","summary":"Kevin Tang, chair of the board, will succeed Peter Greenleaf as chief executive officer at Aurinia.Peter Greenleaf will continue as a consultant to support the transition.Ryan Cole was appointed chief operating officer, and Michael Hearne was appointed chief financial officer.Thomas Wei was appointed chief scientific officer, while Stew Kroll and Stephen Robertson will remain chief development officer and general counsel.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire  on March 23, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL1w808F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621708787","title":"Aurinia Pharmaceuticals Inc - Appoints Kevin Tang as CEO Succeeding Peter Greenleaf","url":"https://stock-news.laohu8.com/highlight/detail?id=2621708787","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621708787?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:00","pubTimestamp":1774267205,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nTUA5XDTX9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621228708","title":"Aurinia Pharmaceuticals Inc - Appoints Michael Hearne as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2621228708","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621228708?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:00","pubTimestamp":1774267205,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nTUA5XDTX9:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619714927","title":"13D Filings -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2619714927","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619714927?lang=en_us&edition=fundamental","pubTime":"2026-03-14 08:29","pubTimestamp":1773448140,"startTime":"0","endTime":"0","summary":"These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from March 5 through March 11, 2026. Source: VerityData. Mercury Systems  Jana Partners Management reduced its stake in the aerospace and defense contractor to 4,114,618 shares. Jana Partners did so through the sale of 852,057 Mercury shares from Feb. 9 through March 4 at per share prices ranging from $81 to $94.05. Following the latest sales, Jana Partners continues to own a 6.9% stake in Mercury Systems' outstanding stock. Shares of Mercury Systems have gained about 13.1% in value in 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZD","MRCY","PBF","BK4077","IE0034390439.USD","IE00B19Z6F94.USD","WRB","BK4107","BK4187","BK4588","BK4139","AUPH","BK4138","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618622017","title":"The Bull Case For Aurinia Pharmaceuticals (AUPH) Could Change Following Strong 2025 Results And Upbeat 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2618622017","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618622017?lang=en_us&edition=fundamental","pubTime":"2026-03-09 21:26","pubTimestamp":1773062785,"startTime":"0","endTime":"0","summary":"In February 2026, Aurinia Pharmaceuticals reported fourth-quarter 2025 revenue of US$77.11 million and full-year revenue of US$283.06 million, alongside a very large increase in net income and earnings per share versus 2024. \nOn the same day, the company issued 2026 guidance calling for total revenue of US$315 million to US$325 million and net product sales of US$305 million to US$315 million, signaling management’s confidence in its operating momentum and product demand. \nWe’ll now examine...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/the-bull-case-for-aurinia-pharmaceuticals-auph-could-change","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/the-bull-case-for-aurinia-pharmaceuticals-auph-could-change","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617363873","title":"Angkor Resources Closes $4.8M Sale of Evesham Oil and Gas Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2617363873","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617363873?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:30","pubTimestamp":1772803852,"startTime":"0","endTime":"0","summary":"Angkor Resources Corp. has closed the sale of its 40% participating interest in the Evesham Macklin oil and gas lands in Saskatchewan to 2196231 Alberta Ltd. for $4.8 million. The company said all payments have been received, the deal eliminates $3.8 million in debt and provides $1.0 million in net proceeds, and it plans to focus on advancing its Cambodian Block VIII onshore oil and gas project and mineral exploration programs.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL80M1Sp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AUPH","EMR.AU","BK7104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617701055","title":"Aurinia Pharmaceuticals Earnings Call Highlights Growth And Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2617701055","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617701055?lang=en_us&edition=fundamental","pubTime":"2026-03-06 08:21","pubTimestamp":1772756510,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals (($AUPH)) has held its Q4 earnings call. Read on for the main highlights of the call. Aurinia Pharmaceuticals struck an opt...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aurinia-pharmaceuticals-earnings-call-highlights-growth-and-risks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aurinia-pharmaceuticals-earnings-call-highlights-growth-and-risks?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AUPH"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.auriniapharma.com","stockEarnings":[{"period":"1week","weight":-0.0044},{"period":"1month","weight":0.112},{"period":"3month","weight":0.0998},{"period":"6month","weight":0.344},{"period":"1year","weight":0.9728},{"period":"ytd","weight":0.0019}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.087},{"period":"3month","weight":0.0359},{"period":"6month","weight":0.0542},{"period":"1year","weight":0.3059},{"period":"ytd","weight":0.047}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.071692},{"month":2,"riseRate":0.416667,"avgChangeRate":0.005745},{"month":3,"riseRate":0.5,"avgChangeRate":0.089864},{"month":4,"riseRate":0.666667,"avgChangeRate":-0.001478},{"month":5,"riseRate":0.545455,"avgChangeRate":-0.008134},{"month":6,"riseRate":0.454545,"avgChangeRate":-0.02016},{"month":7,"riseRate":0.636364,"avgChangeRate":0.041551},{"month":8,"riseRate":0.545455,"avgChangeRate":-0.014541},{"month":9,"riseRate":0.454545,"avgChangeRate":0.063835},{"month":10,"riseRate":0.583333,"avgChangeRate":0.048963},{"month":11,"riseRate":0.583333,"avgChangeRate":0.036405},{"month":12,"riseRate":0.416667,"avgChangeRate":0.092842}],"exchange":"NASDAQ","name":"Aurinia Pharmaceuticals","nameEN":"Aurinia Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aurinia Pharmaceuticals(AUPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aurinia Pharmaceuticals(AUPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aurinia Pharmaceuticals,AUPH,Aurinia Pharmaceuticals股票,Aurinia Pharmaceuticals股票老虎,Aurinia Pharmaceuticals股票老虎国际,Aurinia Pharmaceuticals行情,Aurinia Pharmaceuticals股票行情,Aurinia Pharmaceuticals股价,Aurinia Pharmaceuticals股市,Aurinia Pharmaceuticals股票价格,Aurinia Pharmaceuticals股票交易,Aurinia Pharmaceuticals股票购买,Aurinia Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aurinia Pharmaceuticals(AUPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aurinia Pharmaceuticals(AUPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction